Serum Hormone Levels Among Patients with Prostatic Carcinoma or Benign Prostatic Hyperplasia and Clinic Controls

Hulka, Barbara S.; Hammond, J. E.; DiFerdinando, George T.; Mickey, Don D.; Fried, Floyd A.; Checkoway, Harvey; Stumpf, Walter E.; Beckman, William C.; Clark, Terry D.

doi:10.1016/s0022-5347(17)41661-2

Cited by 6 publications

(6 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Epidemiological studies have failed to demonstrate a consistent, dose‐related correlation between prostate cancer risk and sex hormone levels (Jackson et al, 1977, 1981; Ahluwalia et al, 1981; Meikle and Stanish 1982; Zumoff et al, 1982; Hulka et al, 1987; Nomura et al, 1988; Meikle et al, 1989; Barrett‐Connor et al, 1990; Andersson et al, 1993; Hsing and Comstock 1993; Gann et al, 1996; Nomura et al, 1996; Demark‐Wahnefried et al, 1997; Guess et al, 1997; Vatten et al, 1997; Wolk et al, 1997; Dorgan et al, 1998; Heikkila et al, 1999; Hawk et al, 2000; Shaneyfelt et al, 2000; Mohr et al, 2001; Slater, 2000). A majority of case‐control studies have found no significant association between serum testosterone or dihydrotestosterone (DHT) concentrations and the risk of prostate cancer.…”

Section: Epidemiological Data On the Relationship Between Serum Testomentioning

confidence: 99%

Managing the Risks of Prostate Disease During Testosterone Replacement Therapy in Older Men: Recommendations for a Standardized Monitoring Plan

Bhasin

Singh

Mac

et al. 2003

Journal of Andrology

201

122

View full text Add to dashboard Cite

Section: Epidemiological Data On the Relationship Between Serum Testomentioning

confidence: 99%

Managing the Risks of Prostate Disease During Testosterone Replacement Therapy in Older Men: Recommendations for a Standardized Monitoring Plan

Bhasin

Singh

Mac

et al. 2003

Journal of Andrology

201

122

View full text Add to dashboard Cite

“…Concerns regarding stimulation of benign prostatic hypertrophy (BPH) and prostatic carcinoma have not been supported experimentally. Hulka et al 150 showed no association between testosterone levels and occurrence of prostate cancer. Similarly, Gann et al 151 failed to show any relation between circulating androgen levels and the development of BPH.…”

Section: Sex Steroids In the Management Of Osteoporosismentioning

confidence: 96%

Hormone Replacement Therapy and Fractures in Older Adults

Kamel

Perry

Morley

2001

J American Geriatrics Society

View full text Add to dashboard Cite

Estrogen deficiency in women is associated with accelerated bone loss, and estrogen replacement therapy has been proven to be effective in preventing osteoporosis and fractures in postmenopausal women. The introduction of selective estrogen receptor modulators that have an estrogen-like effect on the skeleton but have a different pattern of effects on other tissues may have an important role in the management of osteoporosis in women in the near future. In men, androgen deficiency has been shown to be associated with osteoporosis. Although androgen replacement in hypogonadal men may decrease bone resorption and increase bone mass, long-term placebo-controlled trials are needed to better define the benefits and risks of such therapy before it can be recommended. Sex hormone deficiency is linked to the development of osteoporosis in both women and men. In women, hormonal replacement by estrogen or the newly developed selective estrogen receptor modulators may prevent the development of osteoporosis and its related fractures. In men, there is early evidence that testosterone replacement therapy may enhance bone mass in hypogonadal men.

show abstract

“…Les 6tudes 6piddmiologiques ont montr6 que le risque de cancer n'est pas corr616 au taux sdrique de testost6rone [3,5].…”

Section: A N D R O G I~n E S E T C a N C E R D E L A P R O S T Aunclassified

Traitement androgénique substitutif et cancer prostatique

Flam

2002

Androl.

View full text Add to dashboard Cite

Les etudes ~pid~miologiques ont montr~ que le risque de cancer de la prostate n'est pas corr~l~ au taux s&ique de testosterone, les androg~nes ne semblent pas pouvoir induire un cancer de la prostate chez I'homme. Par contre, I'apport exog~ne de testosterone peut d~masquer un cancer prostatique jusque I~ frein~ par un hypogonadisme. La d~tection d'un cancer latent avant le debut du traitement doit suivre les r~gles habituelles fond(~es sur le toucher rectal et le taux serique du PSA. Une surveillance semestrielle est justifiee en debut de traitement, ensuite, la surveillance doit ~tre annuelle. l'absence de d6veloppement prostatique. Cependant, les androgenes semblent ensuite avoir un r61e tout ?~ fait passif visa -vis de la prostate.

show abstract

Serum Hormone Levels Among Patients with Prostatic Carcinoma or Benign Prostatic Hyperplasia and Clinic Controls

Cited by 6 publications

References 0 publications

Managing the Risks of Prostate Disease During Testosterone Replacement Therapy in Older Men: Recommendations for a Standardized Monitoring Plan

Managing the Risks of Prostate Disease During Testosterone Replacement Therapy in Older Men: Recommendations for a Standardized Monitoring Plan

Hormone Replacement Therapy and Fractures in Older Adults

Traitement androgénique substitutif et cancer prostatique

Contact Info

Product

Resources

About